Bio-Techne Corp

TECH

Add to Watchlist

44.900USD

-2.520-5.31%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

Bio-Techne Corp's Score

Industry at a Glance

Industry Ranking

27 / 383

Overall Ranking

122 / 4490

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Bio-Techne Corp Highlights

StrengthsRisks

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.

Fairly Valued

The company’s latest PE is 67.19, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 178.19M shares, increasing 0.00% quarter-over-quarter.

Held by Wallace Weitz

Star Investor Wallace Weitz holds 802.95K shares of this stock.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

64.073

Target Price

+32.49%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Bio-Techne Corp is 9.02, ranking 16 out of 383 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 311.42M, representing a year-over-year decrease of 1.51%, while its net profit experienced a year-over-year decrease of 125.98%.

Score

Industry at a Glance

Previous score

9.02

Change

0



Financials

7.62

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.68

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Bio-Techne Corp is 4.22, ranking 374 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is 67.19, which is 112.71% below the recent high of 142.92 and 49.80% above the recent low of 33.73.

Score

Industry at a Glance

Previous score

4.22

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/383

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Bio-Techne Corp is 8.00, ranking 161 out of 383 in the Biotechnology & Medical Research industry. The average price target is 70.00, with a high of 75.00 and a low of 60.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Bio-Techne Corp is 6.81, ranking 183 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 58.22 and the support level at 40.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.81

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Bio-Techne Corp is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 113.81%, representing a quarter-over-quarter increase of 3.16%. The largest institutional shareholder is Lee Ainslie, holding a total of 3.85M shares, representing 2.46% of shares outstanding, with 637.51% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

9.14M

+3.99%

State Street Investment Management (US)

5.81M

+1.02%

Wellington Management Company, LLP

5.73M

+12.10%

Geode Capital Management, L.L.C.

4.93M

+0.05%

Atlanta Capital Management Company, L.L.C.

4.83M

-2.34%

MFS Investment Management

3.91M

+169.79%

Maverick Capital, Ltd.

Star Investors

3.85M

+27.82%

T. Rowe Price Associates, Inc.

Star Investors

3.85M

+23.23%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bio-Techne Corp is 7.52, ranking 11 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 1.38. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Bio-Techne Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Bio-Techne Corp

TECH

7.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment